Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients.

ABSTRACT:

Introduction

Subclinical inflammation is an important predictor of death-censored graft loss, and its treatment has been shown to improve graft outcomes. Urine CXCL10 outperforms standard post-transplant surveillance in observational studies, by detecting subclinical rejection and early clinical rejection before graft functional decline in kidney transplant recipients.

Methods and analysis

This is a phase ii/iii multicentre, international randomised controlled parallel group trial to determine if the early treatment of rejection, as detected by urine CXCL10, will improve kidney allograft outcomes. Incident adult kidney transplant patients (n~420) will be enrolled to undergo routine urine CXCL10 monitoring postkidney transplant. Patients at high risk of rejection, defined as

SUBMITTER: Ho J 

PROVIDER: S-EPMC6500325 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature